Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Holding JP:4519?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
58.99Last Year’s EPS
55.43Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 24, 2018
|% Change Since: -0.22%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with increased revenue and profit, driven by the success of key products like Hemlibra and Actemra. There were significant upward revisions in the forecast, indicating positive future expectations. However, domestic sales faced challenges and there were discontinuations in the development pipeline. Overall, the positive aspects outweigh the challenges.Company Guidance
During Chugai Pharmaceutical’s earnings call for the third quarter of fiscal year 2024, several key financial metrics and strategic developments were discussed. Revenue increased by 3.7% year-on-year, reaching ¥868.5 billion, while operating profit saw a significant rise of 25.3% to ¥426.6 billion. This performance prompted an upward revision of the full-year forecast, with revenue now projected at ¥1,150 billion and operating profit at ¥540 billion, each revised upwards by ¥80 billion. The increase was largely driven by strong overseas sales, particularly of Hemlibra and Actemra, which exceeded expectations. Domestic sales faced a decline due to the completion of government supply of Ronapreve and the impact of generics. Chugai also highlighted progress in its R&D pipeline, notably with products like PiaSky and Alecensa, and emphasized its commitment to global healthcare contributions through new product launches. The company maintained a cautious outlook for the next fiscal year, anticipating revenue and operating profit levels similar to the revised forecast for this fiscal year amidst prevailing uncertainties.Revenue and Profit Increase
Revenue increased by 3.7% year-on-year, and operating profit increased by 25.3% year-on-year.
Upward Revision of Forecast
The initial forecast has been revised upwards to revenue of ¥1,150 billion and operating profit to ¥540 billion, an increase of ¥80 billion each.
Strong Performance of Hemlibra and Actemra
Hemlibra exports have been revised upwards by ¥36.7 billion, and Actemra exports have been revised upwards by ¥21.2 billion. Overall overseas sales increased by ¥105.8 billion or 33.8% year-on-year.
Foundation for Growth
Significant progress in strengthening the foundation for growth with Chugai-originated products like PiaSky, NEMLUVIO, and Alecensa.
R&D Advancements
Approvals for in-house products PiaSky and Alecensa, and ongoing development of NXT007 and GYM329.
---
JP:4519 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JP:4519 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | ¥6380.00 | ¥6366.00 | -0.22% |
| Oct 25, 2024 | ¥6942.00 | ¥6869.00 | -1.05% |
| Jul 25, 2024 | ¥6162.00 | ¥6026.00 | -2.21% |
| Apr 24, 2024 | ¥5148.42 | ¥5114.66 | -0.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Chugai Pharmaceutical Co Ltd (JP:4519) report earnings?
Chugai Pharmaceutical Co Ltd (JP:4519) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Chugai Pharmaceutical Co Ltd (JP:4519) earnings time?
Chugai Pharmaceutical Co Ltd (JP:4519) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Chugai Pharmaceutical Co Ltd stock?
The P/E ratio of Chugai Pharmaceutical Co is N/A.
What is JP:4519 EPS forecast?
JP:4519 EPS forecast for the fiscal quarter 2024 (Q4) is 58.99.
---